These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1595 related articles for article (PubMed ID: 8435428)

  • 1. Specific release of cytokines by lymphocytes infiltrating human melanomas in response to shared melanoma antigens.
    Hom SS; Schwartzentruber DJ; Rosenberg SA; Topalian SL
    J Immunother Emphasis Tumor Immunol; 1993 Jan; 13(1):18-30. PubMed ID: 8435428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Common expression of melanoma tumor-associated antigens recognized by human tumor infiltrating lymphocytes: analysis by human lymphocyte antigen restriction.
    Hom SS; Topalian SL; Simonis T; Mancini M; Rosenberg SA
    J Immunother (1991); 1991 Jun; 10(3):153-64. PubMed ID: 1868040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of naturally processed and HLA-A1-presented melanoma T-cell epitopes defined by CD8(+) T-cells' release of granulocyte-macrophage colony-stimulating factor but not by cytolysis.
    Maeurer MJ; Martin D; Elder E; Storkus WJ; Lotze MT
    Clin Cancer Res; 1996 Jan; 2(1):87-95. PubMed ID: 9816095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specific release of granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-alpha, and IFN-gamma by human tumor-infiltrating lymphocytes after autologous tumor stimulation.
    Schwartzentruber DJ; Topalian SL; Mancini M; Rosenberg SA
    J Immunol; 1991 May; 146(10):3674-81. PubMed ID: 1902860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Shared human melanoma antigens. Recognition by tumor-infiltrating lymphocytes in HLA-A2.1-transfected melanomas.
    Kawakami Y; Zakut R; Topalian SL; Stötter H; Rosenberg SA
    J Immunol; 1992 Jan; 148(2):638-43. PubMed ID: 1729379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of cytokine release of unselected and CD8+ selected renal cell carcinoma tumor-infiltrating lymphocytes (TIL). Evidence for enhanced specific killing of tumor necrosis factor-secreting/IL-6 nonsecreting TIL in vitro and correlation with complete response in vivo.
    Steger GG; Pierce WC; Figlin R; Czernin J; Kaboo R; DeKernion JB; Okarma T; Belldegrun A
    Clin Immunol Immunopathol; 1994 Aug; 72(2):237-47. PubMed ID: 8050198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of lymphocytes infiltrating human breast cancer: specific immune reactivity detected by measuring cytokine secretion.
    Schwartzentruber DJ; Solomon D; Rosenberg SA; Topalian SL
    J Immunother (1991); 1992 Jul; 12(1):1-12. PubMed ID: 1637779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced expression of HLA molecules and stimulation of autologous human tumor infiltrating lymphocytes following transduction of melanoma cells with gamma-interferon genes.
    Ogasawara M; Rosenberg SA
    Cancer Res; 1993 Aug; 53(15):3561-8. PubMed ID: 8101762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-infiltrating lymphocytes from human ovarian cancer patients recognize autologous tumor in an MHC class II-restricted fashion.
    Dadmarz RD; Ordoubadi A; Mixon A; Thompson CO; Barracchini KC; Hijazi YM; Steller MA; Rosenberg SA; Schwartzentruber DJ
    Cancer J Sci Am; 1996; 2(5):263-72. PubMed ID: 9166543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes. Evidence for shared tumor antigens.
    Darrow TL; Slingluff CL; Seigler HF
    J Immunol; 1989 May; 142(9):3329-35. PubMed ID: 2785141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHC-tumor peptide interactions.
    Gervois N; Guilloux Y; Diez E; Jotereau F
    J Exp Med; 1996 May; 183(5):2403-7. PubMed ID: 8642353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defective lymphokine production by most CD8+ and CD4+ tumor-specific T cell clones derived from human melanoma-infiltrating lymphocytes in response to autologous tumor cells in vitro.
    Guilloux Y; Viret C; Gervois N; Le Dréan E; Pandolfino MC; Diez E; Jotereau F
    Eur J Immunol; 1994 Sep; 24(9):1966-73. PubMed ID: 7522155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-infiltrating lymphocytes derived from select B-cell lymphomas secrete granulocyte-macrophage colony-stimulating factor and tumor necrosis factor-alpha in response to autologous tumor stimulation.
    Schwartzentruber DJ; Stetler-Stevenson M; Rosenberg SA; Topalian SL
    Blood; 1993 Aug; 82(4):1204-11. PubMed ID: 8353284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T-cell receptor usage by melanoma-specific clonal and highly oligoclonal tumor-infiltrating lymphocyte lines.
    Shilyansky J; Nishimura MI; Yannelli JR; Kawakami Y; Jacknin LS; Charmley P; Rosenberg SA
    Proc Natl Acad Sci U S A; 1994 Mar; 91(7):2829-33. PubMed ID: 7511820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
    Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
    J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clone.
    Sensi M; Salvi S; Castelli C; Maccalli C; Mazzocchi A; Mortarini R; Nicolini G; Herlyn M; Parmiani G; Anichini A
    J Exp Med; 1993 Oct; 178(4):1231-46. PubMed ID: 8376931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1.
    Rivoltini L; Kawakami Y; Sakaguchi K; Southwood S; Sette A; Robbins PF; Marincola FM; Salgaller ML; Yannelli JR; Appella E
    J Immunol; 1995 Mar; 154(5):2257-65. PubMed ID: 7868898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recognition of shared melanoma antigen by HLA-A2-restricted cytolytic T cell clones derived from human tumor-infiltrating lymphocytes.
    Viret C; Davodeau F; Guilloux Y; Bignon JD; Semana G; Breathnach R; Jotereau F
    Eur J Immunol; 1993 Jan; 23(1):141-6. PubMed ID: 8419164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recognition of neuroectodermal tumors by melanoma-specific cytotoxic T lymphocytes: evidence for antigen sharing by tumors derived from the neural crest.
    Shamamian P; Mancini M; Kawakami Y; Restifo NP; Rosenberg SA; Topalian SL
    Cancer Immunol Immunother; 1994 Aug; 39(2):73-83. PubMed ID: 7519127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MHC-restricted recognition of autologous melanoma by tumor-specific cytotoxic T cells. Evidence for restriction by a dominant HLA-A allele.
    Crowley NJ; Darrow TL; Quinn-Allen MA; Seigler HF
    J Immunol; 1991 Mar; 146(5):1692-9. PubMed ID: 1671580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 80.